论文部分内容阅读
作者对SmithKline Beecham公司研制的莱姆病疫苗[脂蛋白-外表面蛋白A(Lipo-OspA)疫苗]在健康成人接种12个月后的抗体持久性及12个月时的加强免疫效果进行了评估。受试对象为20名健康成年志愿者,按0、 1和2月程序接种Lipo-OspA疫苗, 12个月后加强免疫1次。分别在加强免疫前及加强免疫后1、6和12个月采集血样,用抑制ELISA法测定LA-2等价抗OspA抗体滴度,同时对加强免疫后的安全性进行评估。
The authors evaluated the durability of antibodies to Lyme disease vaccine [Lipo-OspA vaccine developed by SmithKline Beecham, Inc.] 12 months after vaccination in healthy adults and the boosting effect at 12 months . The subjects were 20 healthy adult volunteers. The Lipo-OspA vaccine was administered on a 0, 1 and 2 month schedule and boosted at 12 months. Blood samples were taken at 1, 6 and 12 months after booster immunization and booster immunization respectively. The titer of LA-2 equivalent anti-OspA antibody was measured by ELISA, and the safety after booster immunization was evaluated.